JP Morgan Chase’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4
| Closed | -$10 | – | 7840 |
|
|
2025
Q4 | $10 | Hold |
4
| – | – | ﹤0.01% | 7335 |
|
|
2025
Q3 | $7 | Hold |
4
| – | – | ﹤0.01% | 7331 |
|
|
2025
Q2 | $6 | Hold |
4
| – | – | ﹤0.01% | 6998 |
|
|
2025
Q1 | $4 | Sell |
4
-85,798
| -100% | -$103K | ﹤0.01% | 7236 |
|
|
2024
Q4 | $112K | Buy |
85,802
+85,798
| +2,144,950% | +$256K | ﹤0.01% | 5708 |
|
|
2024
Q3 | $14 | Hold |
4
| – | – | ﹤0.01% | 7275 |
|
|
2024
Q2 | $13 | Hold |
4
| – | – | ﹤0.01% | 7196 |
|
|
2024
Q1 | $19 | Hold |
4
| – | – | ﹤0.01% | 7175 |
|
|
2023
Q4 | $29 | Sell |
4
-8,147
| -100% | -$45.6K | ﹤0.01% | 7285 |
|
|
2023
Q3 | $98.5K | Buy |
8,151
+6,633
| +437% | +$68.5K | ﹤0.01% | 5479 |
|
|
2023
Q2 | $16.1K | Buy |
1,518
+39
| +3% | +$402 | ﹤0.01% | 5963 |
|
|
2023
Q1 | $15K | Buy |
1,479
+29
| +2% | +$333 | ﹤0.01% | 6041 |
|
|
2022
Q4 | $21K | Sell |
1,450
-21,771
| -94% | -$326K | ﹤0.01% | 5871 |
|
|
2022
Q3 | $282K | Buy |
23,221
+1,046
| +5% | +$13.5K | ﹤0.01% | 4783 |
|
|
2022
Q2 | $311K | Sell |
22,175
-2,864
| -11% | -$33.7K | ﹤0.01% | 4836 |
|
|
2022
Q1 | $356K | Buy |
25,039
+1,253
| +5% | +$18.6K | ﹤0.01% | 4890 |
|
|
2021
Q4 | $502K | Sell |
23,786
-4,768
| -17% | -$112K | ﹤0.01% | 4820 |
|
|
2021
Q3 | $750K | Buy |
28,554
+26,765
| +1,496% | +$865K | ﹤0.01% | 4501 |
|
|
2021
Q2 | $56K | Sell |
1,789
-182,688
| -99% | -$5.98M | ﹤0.01% | 5703 |
|
|
2021
Q1 | $5.66M | Buy |
184,477
+184,450
| +683,148% | +$6.27M | ﹤0.01% | 2861 |
|
|
2020
Q4 | $1K | Buy |
+27
| New | +$807 | ﹤0.01% | 5561 |
|
JP Morgan Chase's RPTX Position: Q1 2026 in Review
JP Morgan Chase sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 4 shares — an estimated $10 sold.
JP Morgan Chase first reported a position in RPTX in Q4 2020 and held it in 21 quarters. The position peaked at $5.66M in Q1 2021. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- JP Morgan Chase reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 4 Repare Therapeutics shares in Q1 2026, an estimated $10.
- JP Morgan Chase first reported a position in Repare Therapeutics in Q4 2020 and held it in 21 quarters.
- JP Morgan Chase's Repare Therapeutics position peaked at $5.66M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.